LMC | MANNA RESEARCH NEWS
Latest on what is going on with LMC | MANNA RESEARCH and industry newsLet’s Connect: LMC Manna Research will be in attendance at ATTD in Madrid, Spain & SCOPE in Orlando, Florida! Will we see you there?
ATTD & SCOPE 2020 Conference Blog Post
Let’s Connect: LMC Manna Research will be attending the SCRS Global Oncology Site Summit in Austin, Texas!
LMC Manna Research will be in Austin, Texas for the SCRS Global Oncology Site Summit from Friday January 31st – Saturday February 1st. At this year’s summit, we are looking forward to come together as an industry to communicate and collaborate on opportunities within...
Check out the most recent publication about The Canadian Diabetes Prevention Program (CDPP) on The Globe and Mail!
The Canadian Diabetes Prevention Program (CDPP) is a collaboration of Diabetes Canada and LMC Healthcare, LMC Manna Research's clinical counterpart. The new lifestyle change program is part of a national initiative that will help Canadians with prediabetes or multiple...
LMC Manna Research is proud to announce our #partnership with TrialScout , the world’s first #patientengagement platform allowing #sharing of #PatientExperience at the research site level.
Read the post here: https://lnkd.in/gd76ghs #clinicaltrials #makinghealthyeasier #SCRS19 Also, hyperCORE International has partnered to implement across the entire #supernetwork #ResearchAccelerated Read their release here: https://lnkd.in/geawr7g
LMC Manna Research opens two new locations, expanding presence in Canada’s Capital and NASH/NAFLD research in London, Ontario
Check out the Cision press release featuring Manna's newest sites in Ottawa and London, and how these new clinics will help bring more research opportunities to even more Canadians as well as give sponsors and CROs access to key areas in primary care and NASH/NAFLD....
Xeris scores first FDA nod with shelf-stable glucagon injector, syringe | FiercePharma
Exciting news for our sponsor Xeris Pharmaceutical: FDA has approved Xeris’s Gvoke pen to treat severe hypoglycemia in pediatric and adult diabetes patients over the age of two. The FDA approval was based on data from three phase 3 clinical trials showing Gvoke’s 100%...